Perindopril

Generic Name: Perindopril

Brand Names: Aceon, Coversyl, Prestalia, Viacoram

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₃₂N_₂O_₅

CAS Number: 82834-16-0

Unique Ingredient Identifier: Y5GMK36KGY

Background: Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) ...

Indication: For the treatment of mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.

Associated Conditions: Cardiovascular Events, Diabetic Nephropathy, Hypertension, Hypertension, Essential Hypertension, Myocardial Infarction, NYHA Class I Congestive heart failure, Stroke, Chronic heart failure with reduced ejection fraction (NYHA Class II), Chronic heart failure with reduced ejection fraction (NYHA Class III)

Associated Therapies: -

Clinical Trials

Comparison of Medical Therapies in Marfan Syndrome.

Phase 4

Completed

Conditions: Marfan Syndrome

Interventions: Drug: VERAPAMIL
Drug: Atenolol
Drug: Perindopril

First Posted Date: 2011-02-14

Last Posted Date: 2011-02-14

Lead Sponsor: Cardiff University

Target Recruit Count: 18

Registration Number: NCT01295047

Locations: 🇬🇧
Wales Heart Research Institute, Cardiff University, Cardiff, United Kingdom

AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)

Phase 2

Completed

Conditions: Abdominal Aortic Aneurysm

Interventions: Drug: placebo
Drug: perindopril arginine
Drug: amlodipine 5mgs

First Posted Date: 2010-05-06

Last Posted Date: 2021-01-26

Lead Sponsor: Imperial College London

Target Recruit Count: 224

Registration Number: NCT01118520

Locations: 🇬🇧
Royal Free Hospital, London, United Kingdom
🇬🇧
The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, United Kingdom
🇬🇧
Colchester Hospital, Colchester, United Kingdom

and more 6 locations

Angiotensin Receptor Blocker Combined With Calcium Antagonist Evaluation of Safety and Lowering of Systolic Blood Pressure Study

Phase 4

Withdrawn

Conditions: Hypertension

Interventions: Drug: Perindopril/amlodipine
Drug: Olmesartan/amlodipine
Drug: Perindopril

First Posted Date: 2010-03-18

Last Posted Date: 2015-06-03

Lead Sponsor: Monash University

Registration Number: NCT01089452

Locations: 🇦🇺
Alfred Hospital, Melbourne, Victoria, Australia

An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence

Phase 1

Completed

Conditions: Methamphetamine Abuse
Methamphetamine Dependence
Substance Abuse

Interventions: Drug: Placebo
Drug: Perindopril
Drug: Candesartan

First Posted Date: 2010-02-04

Last Posted Date: 2022-04-26

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 80

Registration Number: NCT01062451

Locations: 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, Texas, United States

Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fasted Conditions

Not Applicable

Completed

Conditions: Essential Hypertension

First Posted Date: 2009-11-13

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 48

Registration Number: NCT01012687

Locations: 🇺🇸
Novum Pharmaceutical Research Services, Houston, Texas, United States

Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fed Conditions

Not Applicable

Completed

Conditions: Essential Hypertension

First Posted Date: 2009-11-13

Last Posted Date: 2018-01-23

Lead Sponsor: Roxane Laboratories

Target Recruit Count: 48

Registration Number: NCT01013155

Locations: 🇺🇸
Novum Pharmaceutical Research Services, Houston, Texas, United States

Chronic Subdural Hematoma - Reduction of Recurrence by Treatment With Angiotensin Converting Enzyme Inhibitors

Not Applicable

Terminated

Conditions: Hematoma, Subdural, Chronic

Interventions: Drug: Placebo
Drug: Perindopril

First Posted Date: 2009-06-08

Last Posted Date: 2020-08-19

Lead Sponsor: Odense University Hospital

Target Recruit Count: 47

Registration Number: NCT00915928

Efficacy of Perindopril to Prevent Recurrence of Atrial Fibrillation in Patients With Essential Hypertension

Phase 3

Completed

Conditions: Atrial Fibrillation
Essential Hypertension

Interventions: Drug: Perindopril

First Posted Date: 2007-04-18

Last Posted Date: 2020-02-21

Lead Sponsor: Montreal Heart Institute

Target Recruit Count: 316

Registration Number: NCT00461903

Locations: 🇨🇦
Montreal Heart Institute, Montreal, Quebec, Canada

S90652 in Paediatric Hypertension

Phase 2

Completed

Conditions: Hypertension

First Posted Date: 2005-09-20

Last Posted Date: 2018-04-12

Lead Sponsor: Institut de Recherches Internationales Servier

Target Recruit Count: 50

Registration Number: NCT00202592

Locations: 🇫🇷
Hôpital Necker Enfants Malades, Paris, France

S90652 in Paediatric Hypertension

Phase 2

Completed

Conditions: Hypertension

First Posted Date: 2005-09-20

Last Posted Date: 2018-04-11

Lead Sponsor: Institut de Recherches Internationales Servier

Target Recruit Count: 50

Registration Number: NCT00202553

Locations: 🇫🇷
Hôpital Necker Enfants Malades, Paris, France

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy